On the subject of enhancing CAR-T cell activity by editing PD-1, California-based Caribou Biosciences has recently reported results from a Phase 1 study in relapsed or refractory B cell non-Hodgkin lymphoma.
Caribou’s trial is the first to use PD-1 editing in allogeneic CAR-T to enhance persistence by preventing rejection or rapid exhaustion of the cells.
Initial trial data, reported last month, looked spectacular. Following a single dose of 40 million CAR-T cells, 100% ORR (5 of 5 patients) and 80% CR (4 of 5 patients) was achieved.
However, reporting this month of 6 month results has revealed that just 40% of patients remained in CR (2 of 5 patients), raising questions about the success of Caribou’s approach in tackling the issue of durability, which has been a widespread issue for developers of allogeneic CAR-Ts.
Caribou will now double its dose and results are worthwhile keeping an eye on.
Prescient’s OmniCAR, which can be used with allogeneic CAR-T, and its CellPryme M and CellPryme A platforms all address the challenge of cell persistence.
https://www.cariboubio.com/https://www.fiercebiotech.com/biote...t-hit-durability-doubts-half-patients-relapseCRISPR Therapeutics has reported initial data from its Phase I study of CTX130, an allogeneic CAR-T cell therapy, in patients with peripheral T-cell lymphoma and cutaneous T-cell lymphoma.
At the data cut off point, the trial had 19 patients enrolled - 8 with peripheral T-cell lymphoma and 10 with cutaneous T-cell lymphoma. All patients and had been heavily pre-treated with a median of four systemic therapies, had a median CD70 expression of 90% and were refractory up to their last therapy line.
At the third dose level and above, ORR was 70% with 30% of patients achieving a CR. In addition, 90% of patients at this level had clinical benefit defined as a stable disease or better response. ORR was 80% in PTCL and 60% in CTCL.
Another one to keep an eye on as Prescient now focuses on targeting PTCL with PTX-100 in a Phase 1b expansion cohort.
https://crisprtx.gcs-web.com/news-r...peutics-presents-positive-results-its-phase-1CRISPR Therapeutics Presents Positive Results from its Phase 1 COBALT™-LYM Trial of CTX130™ in Relapsed or Refractory T Cell Malignancies at the 2022 European Hematology Association (EHA) Congress | BioSpacehttps://www.biospace.com/article/-c...rug-candidate-found-safe-in-early-data-/?s=89
